Lava Therapeutics Bv Stock Price, News & Analysis

LAVA Therapeutics, a clinical-stage immuno-oncology company, announced that data from its Phase 1/2a study on LAVA-1207 will be presented at the ASCO GU Symposium in San Francisco from February 16-18, 2023. The presentation will focus on the early dose escalation of LAVA-1207, a bispecific gamma-delta T cell engager, in patients with therapy-refractory metastatic castration-resistant prostate cancer (mCRPC). The abstract (153) will be part of Poster Session A on February 16. LAVA aims to transform cancer treatment using its Gammabody™ platform and is also conducting trials with its lead candidate LAVA-051 for various hematologic malignancies.

LAVA Therapeutics announced the appointment of Peter A. Kiener, DPhil, and Mary E. Wadlinger to its Board of Directors, effective January 1, 2023. Kiener brings extensive experience in biologics and immunotherapy, having held leadership roles at multiple biopharmaceutical companies. Wadlinger has a strong background in human resources within the biotech sector. This transition follows Guido Magni's departure from the board, who contributed significantly since 2018. The new appointments aim to advance LAVA's strategy in developing bispecific gamma delta T cell engagers for cancer treatment.

LAVA Therapeutics, a clinical-stage immuno-oncology company, announced that CEO Stephen Hurly will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The presentation will take place from 10:30 a.m. to 11:10 a.m. PST. Interested parties can access a webcast of the presentation on the LAVA Therapeutics investor relations website, with a replay available for 90 days. The company focuses on its proprietary Gammabody™ platform, developing bispecific gamma-delta T cell engagers targeting various cancers, including multiple myeloma.

LAVA Therapeutics (Nasdaq: LVTX) announced a poster presentation at the 64th ASH Annual Meeting showcasing initial data from its ongoing Phase 1/2a trial of LAVA-051. The study targets patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).

The preliminary results indicate successful dose escalation to 200 µg without significant toxicity or cytokine release syndrome. The therapy demonstrated predictable pharmacokinetics and early signs of clinical activity, with ongoing dose escalations in the US and EU.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced key developments in its pipeline and financial results for Q3 2022. Notable highlights include the presentation of interim clinical data for LAVA-051 in treating relapsed or refractory chronic lymphocytic leukemia and multiple myeloma at the ASH Annual Meeting. Additionally, LAVA secured a $50 million upfront payment from Seagen for an exclusive worldwide license agreement on LAVA-1223, providing a cash runway beyond 2024. Research and license revenue for Q3 reached $15.3 million, up from $2.1 million in 2021.

LAVA Therapeutics, a clinical-stage immuno-oncology company focused on bispecific gamma delta T cell engagers, announced that CEO Stephen Hurly will present at the Jefferies London Healthcare Conference.

The presentation is scheduled for November 17, 2022, from 8:00 a.m. to 8:30 a.m. GMT (3:00 a.m. to 3:30 a.m. EST). A webcast will be available in the investor relations section of their website and archived for 90 days afterward.

LAVA Therapeutics (Nasdaq: LVTX) announced it will present updated data from its ongoing Phase 1/2a clinical trial of LAVA-051 at the ASH Annual Meeting, December 10-13, 2022. This data will include safety, pharmacodynamics, and pharmacokinetics, along with first results from subcutaneous administration and updates on intravenous dosing cohorts. The lead candidate targets relapsed/refractory multiple myeloma and chronic lymphocytic leukemia. The presentation is scheduled for December 10, 2022, by Arnon P. Kater, M.D., Ph.D.

LAVA Therapeutics, a clinical-stage immuno-oncology company (Nasdaq: LVTX), has appointed Fred M. Powell as its new Chief Financial Officer effective immediately. Mr. Powell brings over 20 years of CFO experience in the biopharmaceutical sector, including significant roles in investor relations and strategic planning. Previously, he led the financial team at Antares Pharma, contributing to its successful $1 billion acquisition. CEO Stephen Hurly welcomed Powell, highlighting his expertise in driving growth initiatives crucial for LAVA's bispecific gamma delta T cell engagers pipeline, particularly LAVA-051 and LAVA-1207.

LAVA Therapeutics (Nasdaq: LVTX) has announced it will present clinical data for LAVA-051 during the Society for Immunotherapy of Cancer’s 37th Annual Meeting from November 8-12, 2022. The presentation will focus on the mechanism of action of LAVA-051, a bispecific gamma delta T cell engager, confirming pharmacodynamics in a clinical setting. Chief Medical Officer Benjamin Winograd will present the findings on November 11, 2022.

LAVA’s Gammabody™ platform aims to treat solid and hematological malignancies.